Antivirals

GSK 2838232 is a HIV-1 maturation inhibitor with action on HIV-1 Gag protein cleavage and is used for research on HIV treatment.

Atazanavir is a HIV-1 protease inhibitor, used in the anti-retroviral therapy of adult and sometimes paediatric patients infected with HIV. In in vitro studies with human pulmonary epithelial cells, atazanavir has been studied as a potential inhibitor of SARS-CoV-2 Mpro protease, with the aim of halting viral replication.

Abacavir sulfate is an antiviral drug that belongs to the class of HIV protease inhibitors. It is used in combination with other antiretroviral drugs to treat HIV-1 infection. Abacavir sulfate inhibits viral replication by blocking the activity of HIV-1 protease, which is necessary for the production of new virus particles.
Abacavir sulfate is part of our Bio-X ™ Range. These products are aimed at life science researchers who need high quality ready to use products for assay development, screening or other R&D work. With a solubility datasheet and convenient vials, all of our Bio-X ™ products are in stock across our global warehouses for rapid delivery and ease of use.

Triazavirin is an antiviral drug developed against SAR-CoV-2. The action of triazavirin might be due to its ability to inhibit the Mpro protease from SARS viruses. Triazavirin has been clinically tested in the treatment of COVID-19 patients.

Inhibitor of HIV-1 integrase strand transfer; antiviral

Nucleoside reverse transcriptase inhibitor; anti-Hepatitis B virus

Ombitasvir is a NS5A inhibitor antiviral agent with action on hepatitis C virus replication and is used for treating chronic hepatitis C in combination therapies.

Cidofovir is an anti-viral agent that is used to treat Cytomegalovirus (CMV) retinitis in patients with AIDS. This drug suppresses CMV replication by inhibiting viral DNA synthesis.

Inhibitor of viral protein NS5B

Inhibitor of viral neuraminidase enzyme, effective against influenza A and B viruses. This antiviral compound inhibits neuraminidase-mediated cleavage of host cell sialic acids, which interact with newly synthesised virions from the host cell. This prevents virion budding from the host, resulting in inhibition of virion release and viral infection overall.

Ledipasvir D-tartrate is an antiviral compound, which is a direct-acting antiviral agent used in the treatment of hepatitis C virus (HCV) infection. It originates from synthetic sources designed to inhibit the replication of specific viral proteins. Ledipasvir functions by targeting the NS5A protein of the hepatitis C virus, a key component necessary for viral replication. By binding to this protein, Ledipasvir disrupts and inhibits the HCV replication complex, effectively suppressing the viral load in patients.

Etravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) medication used in the treatment of human immunodeficiency virus (HIV) infections. It works by blocking reverse transcriptase, an enzyme essential for replication of the virus, thereby preventing the virus from multiplying and spreading. Etravirine is often used in combination with other antiretroviral drugs to effectively treat HIV/AIDS. It is commonly prescribed for patients with virus strains that are resistant to other NNRTI medications due to mutations that confer resistance- mutations K103N and Y181C. Etravirine is a diarylpyrimidine (DAPY) and has conformational isomerism meaning that it binds reverse transcriptase in an fleible manner, under multiple conformations. The impact of specific point mutations in the virus is therefore lessened.

Anti-viral; NS3/4A protease inhibitor

Cytarabine is also known as cytosine arabinoside (ara-C) and is a chemotherapy drug that works by inhibiting DNA synthesis. It acts as a nucleoside analogue, which is incorporated into the growing DNA chain during replication. Cytarabine combines a cytosine base with an arabinose sugar (1β-arabinofuranosylcytosine) and is an analog for human deoxycytosine. Cytarabine interferes with DNA synthesis as it is rapidly converted to cytosine arabinoside triphosphate, damaging DNA when cells are in the synthesis phase (S phase). Tumor cells which are highly mitotic and growing rapidly are therefore preferably targeted. Cytarabine also inhibits nucleotide reductase enzymes as well as nuclear polymerases, leading to interruption and inhibition of synthesis, strand breaks and cell death.

Emtricitabine is an antiviral drug that is used to treat chronic viral hepatitis, which is caused by the hepatitis B and C viruses. The drug blocks the activity of reverse transcriptase, which is an enzyme necessary for the replication of viral RNA in the body. Emtricitabine has been shown to be effective against acute hepatitis B virus infection and chronic hepatitis B virus infection with or without cirrhosis. It also has been shown to be effective against chronic hepatitis C virus infection with or without cirrhosis.

Adefovir is an antiviral drug that is used for the treatment of hepatitis B infections. This drug works by blocking the enzyme reverse transcriptase, therefore preventing the replication of the virus in the body.

Dapivirine is a non-nucleoside reverse transcriptase inhibitor with action on HIV-1 reverse transcriptase and is used for preventing HIV infection through vaginal rings.

Viramidine is a nucleotide analogue prodrug, which is derived from naturally occurring nucleosides, specifically optimized for enhanced therapeutic profiles. Its mode of action involves conversion into ribavirin triphosphate within the body. This active form inhibits viral RNA polymerase, a critical enzyme necessary for viral replication. By disrupting the synthesis of viral RNA, Viramidine effectively reduces viral proliferation within host cells.

HIV-1 Integrase Inhibitor is an antiretroviral compound with a mode of action that blocks the viral enzyme integrase, preventing the integration of viral DNA into the host genome. It is used for the treatment of HIV infection.

Tenofovir diphosphate is an antiviral compound, which is a key active metabolite derived from the prodrugs tenofovir disoproxil fumarate and tenofovir alafenamide, both originating from chemical synthesis. Its mode of action involves inhibiting the activity of HIV-1 reverse transcriptase by competing with the natural substrate, deoxyadenosine 5’-triphosphate, and causing chain termination after incorporation into viral DNA. This mechanism effectively prevents the replication of retroviral DNA, thus halting the progression of the infection.